contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analytiker

Antti Siltanen

Biohit är verksamt inom medicinteknik. Bolaget utvecklar och tillverkar laboratorieutrustning, förnödenheter samt diagnostiska analyssystem anpassade för forskning, vård och industrilaboratorium. Utöver huvudverksamheten erbjuds teknisk support, underhåll samt utbildningstjänster inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget har sitt huvudkontor i Helsingfors.

Biohits nya snabbtest GastroPanel® möjliggör en snabb och tillförlitlig bedömning av risken för magsäckscancer redan vid ett och samma mottagningsbesök. En klinisk studie i Indien visade att testet har hög noggrannhet. Det identifierar bland annat helicobacterinfektioner och slemhinneskador, vilket minskar behovet av gastroskopi och effektiviserar användningen av vårdresurser.                    Inderes              Clinical validation study of Biohit’s GastroPanel® quick test completed in...    Clinical validation study of Biohit’s GastroPanel® quick test completed in IndiaBiohit Oyj Press release 12 May 2025 at 14.00 am local time (EEST)Biohit’s latest innovation, the GastroPanel®...

Biohits aktiekurs har sjunkit, vilket har gjort värderingen mer attraktiv. Bolagets utsikter har inte förändrats, och Inderes förväntar sig tillväxt från nya produkter samt marknadsöppningar. Situationen i Mellanöstern och förändringar i försäljningsmixen kan dock medföra osäkerhet. Bolagets lönsamhet är på en stark nivå, men tillväxt inom OEM-försäljning och distributionsprodukter kan pressa marginalerna. Värderingsmultiplarna är måttliga i förhållande till bolagets tillväxt och risker. Läs mer i denna högkvalitativa analys.                    Inderes              Biohit: Safety margin available again - Inderes    Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Detta meddelande gladde investerarna   BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection Biohit Oyj Press release 6 February 2025 at 11.00 am local time (EEST) BIOHIT Oyj, a pioneer in non-invasive diagnostics for gastrointestinal diseases, has signed a letter of intent (LOI) to collaborate with Singapore-headquartered Restalyst to deliver transformative solutions for early gastric cancer detection. The EU reported approximately 135,600 cases of gastric cancer and 95,400 deaths in 2022, with late-stage diagnosis contributing significantly to the high mortality rate.1 The strategic alignment of BIOHIT and Restalyst underscores their shared commitment to advancing non-invasive gastric cancer risk stratification for early detection. The parties will collaborate among other things on distribution of their technologies, expanding their reach to a broader customer base through their respective networks. Jussi Hahtela, CEO of BIOHIT OYJ, commented: “BIOHIT is proud to join forces with Restalyst. Gastric cancer remains a critical global health challenge, and, by collaboration, we can provide clinicians tools that enable early gastric cancer detection. This partnership not only reinforces our commitment to offer global solutions to global health care challenges but also positions us to expand our reach and impact in the field of gastrointestinal diagnostics.” Zaccheus Peh, CEO of Restalyst, added: “We are very pleased to be entering into this collaboration with BIOHIT. It comes at a time when Restalyst is preparing for a pivotal moment in the company’s journey, one that will enhance our ability to grow and deliver greater value to our stakeholders. Building on this momentum, we are excited to collaborate with BIOHIT to bring innovative, non-invasive solutions for early gastric cancer detection to a wider audience. This partnership represents a significant step towards improving patient outcomes and addressing a critical global health need.”                   Inderes              BIOHIT and Restalyst announce collaboration to improve non-invasive early...    BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detectionBiohit Oyj Press release 6 February 2025 at 11.00 am local time (EEST)BIOHIT Oyj, a pioneer ...

Here is a fresh comment from an analyst regarding yesterday’s “news.”  Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries. The distribution agreement complements Biohit’s product portfolio, which already includes a quick test for celiac disease. We expect modest revenues from the distribution agreement and the news is in line with our strong growth projections.                   Inderes              New distribution rights for Biohit - Inderes    Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries.

Here is a high-quality, comprehensive, and easy-to-read analysis/report on this company in a very interesting “situation.”  Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has achieved a successful turnaround and is targeting strong growth of 15-20% over the 2024-28 strategy period. We expect the company’s earnings to continue to grow in the coming years, supported by the development of new markets and the introduction of new products.                   Inderes              Biohit extensive report: Profitable growth through diagnostics - Inderes    Biohit has achieved a successful turnaround and is targeting strong growth of 15-20% over the 2024-28 strategy period. We expect the company's earnings to continue to grow in the coming years, supported by the development of new markets and new...

Biohit’s GastroPanel® test demonstrated over 90% accuracy in identifying patients at risk of gastric cancer, confirming results from previous studies. The study conducted at Homerton Hospital may facilitate the test’s adoption in the UK NHS, supporting Biohit’s target of 15–20% annual growth. Here are the analyst’s comments on this positive news.                   Inderes              Biohit test receives further proof of its effectiveness in the UK - Inderes    Biohit announced on Wednesday the results of a study of GastroPanel® for the diagnosis of gastric precancerous conditions. The GastroPanel® test on a blood sample identified patients at risk of gastric cancer requiring further examinations with over...

BECAUSE: Approval of Biohit’s GastroPanel® test for use by the British National Health Service (NHS) takes a major step forward Biohit Oyj Press release 8 January 2025 at 10.30 am local time (EEST) A study conducted by a British university hospital confirms the diagnostic accuracy of Biohit’s GastroPanel® test. In the clinical study, the London-based Homerton University Hospital measured the accuracy of the GastroPanel® test in identifying the risk conditions of gastric cancer in patients with upper abdominal complaints. The results confirm the reliability of the GastroPanel® test in screening for gastric cancer risk. The test, which is performed on a blood sample, disclosed the patients at a high risk of gastric cancer and requiring further examinations from those with a healthy stomach with >90% accuracy. This clinical validation study of the GastroPanel® test conducted by Homerton University Hospital is the first of its kind in the UK. The study result is an important breakthrough for the test to be introduced by the British National Health Service (NHS). The use of the test would reduce the need for expensive and painful gastrointestinal endoscopic examinations and provide the patient with a preliminary diagnosis quickly. Currently, endoscopy services in the UK are overburdened and their need is predicted to increase sharply over the next five years. “The GastroPanel® test serves the needs of both patients and healthcare organisations. The rapid identification of gastric cancer risk conditions is important in terms of prevention and effective treatment. With the GastroPanel® test, the patient receives information about their situation quickly and non-invasively, and the test is significantly less expensive for healthcare than an endoscopy. We hope that the approval of the GastroPanel® test will now move forward in the UK,” Biohit CEO Jussi Hahtela says. Biohit’s CTO Panu Hendolin is delighted about the completion of the new clinical study. “The British Society of Gastroenterology recommends screening patients at risk of gastric cancer by using a non-invasive test instead of invasive endoscopy, and the GastroPanel® test meets this need perfectly. The study conducted at Homerton Hospital involved 324 patients and its results are very similar to those of the previously published studies in other countries, so the diagnostic accuracy of the test has been confirmed several times over. The results of the study have recently been published in a British scientific journal

Biohit

Biohit's H1 report exceeded our expectations in terms of both revenue and earnings. The launch of the GastroPanel® fingertip blood test, during H1 and the partial periodization of China's revenue to H2 strengthen our growth expectations for the near future.

<p>We reiterate our Accumulate recommendation for Biohit and raise our target price to EUR 2.4 (previous 2.1). The H1 report exceeded our expectations in terms of both revenue and earnings. The launch of the GastroPanel&reg; fingertip blood test, during H1 and the partial periodization of China's revenue to H2 strengthen our growth expectations for the near future. The valuation picture remains attractive with estimate hikes.</p>

	2022	23e	24e
Omsättning	11,0	12,4	13,6
tillväxt-%	17,0 %	13,2 %	9,9 %
EBIT (adj.)	1,1	1,9	2,2
EBIT-%	10,3 %	15,4 %	16,0 %
EPS (adj.)	0,04	0,11	0,13
Utdelning	0,00	0,00	0,05
Direktavkastning			1,7 %
P/E (just.)	39,3	28,2	23,0
EV/EBITDA	11,4	16,6	14,3

Biohit: Positive result from H1 test

Biohit

Key Estimate Figures2023-08-10